FDA rejects citizen petition claiming Cassava manipulated data, but the biotech's woes are not over
Under fire from all fronts over allegations of data manipulation, Cassava Sciences picked up a small win Thursday, but isn’t out of the woods yet on data manipulation concerns.
The FDA denied a citizen petition from a short seller firm asking the agency to investigate claims that Cassava fudged data for its Alzheimer’s drug, simufilam. But the regulators only rebuffed the petition on procedural grounds, without addressing the accusations, saying the FDA is not legally allowed to initiate investigations based on citizen petition requests.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.